TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 322082

Group type: EXPERIMENTAL
Intervention: Nitrofurantoin macrocrystals (1.2 to 2.4 mg/kg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 30590353

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT) applied to the rectus femoris and gastrocnemius muscles
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Kinesio taping (KT)
Number of subjects: 49
Study: 27629275

Group type: EXPERIMENTAL
Intervention: Higher volumes of plasma expansion (crystalloid and colloid)
Number of subjects: 841
Study: 26044353

Group type: EXPERIMENTAL
Intervention: Tape
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Semi-rigid brace
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Lace-up brace
Number of subjects: 193
Study: 23332236

Group type: EXPERIMENTAL
Intervention: 50 mg etanercept plus methotrexate
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: 25 mg etanercept plus methotrexate
Number of subjects: 604

Group type: COMPARATOR
Intervention: Placebo plus methotrexate
Number of subjects: 604
Study: 21099130

Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA) intervention
Number of subjects: 15534

Group type: COMPARATOR
Intervention: Control group (low EPA concentration)
Number of subjects: 15534
Study: 19468948

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids supplementation (1.3 g daily for 6 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Endurance exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids supplementation
Number of subjects: 0
Study: 18041889

Group type: EXPERIMENTAL
Intervention: Abatacept
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abatacept with TNF-alpha inhibitors
Number of subjects: 0
Study: 15601972

Group type: EXPERIMENTAL
Intervention: DDS System (experimental group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 32
Study: 11329526

Group type: COMPARATOR
Intervention: Provider-reported symptoms
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Patient-reported symptoms
Number of subjects: 1262
Study: 9602398

Group type: EXPERIMENTAL
Intervention: General health screening
Number of subjects: 3064

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 3064
Study: 8288663

Group type: EXPERIMENTAL
Intervention: Closed wound drainage
Number of subjects: 415

Group type: COMPARATOR
Intervention: No postoperative drainage
Number of subjects: 415
Study: 2688978

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 2466
Study: 4915361

Group type: EXPERIMENTAL
Intervention: Bromhexine 16 mg thrice daily for 11 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30970159

Group type: EXPERIMENTAL
Intervention: Cancer-related health factors and general health characteristics
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Self-rated health and life satisfaction
Number of subjects: 321
Study: 28268163

Group type: EXPERIMENTAL
Intervention: Enhanced Twitter intervention (using personal Twitter accounts of editorial board members and trainees)
Number of subjects: 428

Group type: COMPARATOR
Intervention: Control group (no social media engagement)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Basic Twitter intervention (using only the Journal's @JACRJournal Twitter account)
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Enhanced Twitter intervention
Number of subjects: 428

Group type: EXPERIMENTAL
Intervention: Basic Twitter intervention
Number of subjects: 428

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 428
Study: 25833983

Group type: EXPERIMENTAL
Intervention: Whey protein (60 g daily)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Casein (60 g daily)
Number of subjects: 63

Group type: COMPARATOR
Intervention: High or low MC-SFA content (63 g milk fat daily)
Number of subjects: 63
Study: 23580608

Group type: EXPERIMENTAL
Intervention: Alcohol consumption (quantity)
Number of subjects: 580

Group type: EXPERIMENTAL
Intervention: Multiple sexual partners
Number of subjects: 580

Group type: COMPARATOR
Intervention: Unprotected sex events
Number of subjects: 580
Study: 21502454

Group type: EXPERIMENTAL
Intervention: Wound-probing protocol (WPP) with daily probing between staples
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control arm (loose wound closure with staples every 2 cm)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Wound-probing protocol (WPP)
Number of subjects: 76
Study: 19254788

Group type: EXPERIMENTAL
Intervention: Bazedoxifene (20 and 40 mg daily combined)
Number of subjects: 7492
Study: 16270215

Group type: EXPERIMENTAL
Intervention: ProSeal laryngeal mask airway (PLMA)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Classic laryngeal mask airway (CLMA)
Number of subjects: 30
Study: 15311663

Group type: EXPERIMENTAL
Intervention: Equal molar and weight amounts of sucrose, fructose, and glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sucrose, fructose, and glucose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Equal sugar molarities and weights
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucose
Number of subjects: 0
Study: 11194528

Group type: EXPERIMENTAL
Intervention: Calcium intake adjusted for energy intake
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Vitamin A intake
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Calcium intake at lower energy intakes
Number of subjects: 54
Study: 9270085

Group type: EXPERIMENTAL
Intervention: Enalapril combined with hydrochlorothiazide (20/6 mg)
Number of subjects: 374

Group type: COMPARATOR
Intervention: Atenolol (50 mg)
Number of subjects: 374
Study: 8116814

Group type: EXPERIMENTAL
Intervention: Ivermectin plus DEC (400 micrograms/kg plus 1 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ivermectin plus DEC (400 micrograms/kg plus 3 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ivermectin plus DEC (400 micrograms/kg plus 6 mg/kg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: DEC (6 mg/kg) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ivermectin (400 micrograms/kg) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ivermectin (100 micrograms/kg) alone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Ivermectin plus DEC
Number of subjects: 30
Study: 2904883

Group type: EXPERIMENTAL
Intervention: verapamil (240 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: atenolol (100 mg x day‐1)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 30113928

Group type: EXPERIMENTAL
Intervention: CBT
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combined treatment (SSRI + CBT)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 49

Group type: COMPARATOR
Intervention: Combined treatment
Number of subjects: 49

Group type: COMPARATOR
Intervention: SSRI monotherapy
Number of subjects: 49
Study: 28806955

Group type: EXPERIMENTAL
Intervention: SI + Gist
Number of subjects: 163525

Group type: COMPARATOR
Intervention: SI
Number of subjects: 163525
Study: 26554490

Group type: EXPERIMENTAL
Intervention: Directional Microphone (DM) in the Transmitter (Tx)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Omnidirectional Microphone (OM) in the Transmitter (Tx)
Number of subjects: 18
Study: 22339289

Group type: EXPERIMENTAL
Intervention: MTA pulpotomy (PMTA: n = 208)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: CEM pulpotomy (PCEM: n = 205)
Number of subjects: 413
Study: 21969284

Group type: EXPERIMENTAL
Intervention: Dextrose injection (12.5% dextrose)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Lidocaine injection (1% lidocaine solution)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 54
Study: 18360019

Group type: EXPERIMENTAL
Intervention: Triple blockade with 25 mg of spironolactone added to ACE-I (5 mg enalapril) and ARB (50 mg losartan)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group with 1 mg of trichlormethiazide or 20 mg of furosemide added to ACE-I and ARB
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Triple blockade with 25 mg of spironolactone added to ACE-I and ARB
Number of subjects: 32
Study: 17133499

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a and ribavirin (RBV)
Number of subjects: 1046
Study: 14689753

Group type: EXPERIMENTAL
Intervention: Raloxifene
Number of subjects: 178

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 178

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 178
Study: 12516410

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 126

Group type: COMPARATOR
Intervention: Conventional-medicine (placebo: glucose, vitamin C, KCl)
Number of subjects: 126
Study: 9302399

Group type: EXPERIMENTAL
Intervention: Glycyrrhetinic acid (170 mg t.d.s.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Carbenoxolone (100 mg t.d.s.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both inhibitors in combination
Number of subjects: 6
Study: 8475946

Group type: EXPERIMENTAL
Intervention: Enalapril 5 mg per day
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 2427835

Group type: EXPERIMENTAL
Intervention: Celiprolol (200, 400, or 600 mg once daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chlorthalidone (12.5, 25, or 37.5 mg once daily)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Celiprolol
Number of subjects: 66

Group type: COMPARATOR
Intervention: Chlorthalidone
Number of subjects: 66
Study: 31586241

Group type: EXPERIMENTAL
Intervention: Zoledronic acid plus loxoprofen (ZOL + LOX)
Number of subjects: 368

Group type: COMPARATOR
Intervention: Zoledronic acid alone (ZOL)
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Past bisphosphonate users
Number of subjects: 368
Study: 29793629

Group type: EXPERIMENTAL
Intervention: Canakinumab (50, 150, or 300 mg) given subcutaneously once every 3 months
Number of subjects: 10061

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10061
Study: 27149500

Group type: EXPERIMENTAL
Intervention: Intraoperative dexmedetomidine (PRD)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Propofol/remifentanil/saline (PRS)
Number of subjects: 223
Study: 24574431

Group type: EXPERIMENTAL
Intervention: 7% hypertonic saline and 0.1% hyaluronic acid (7% HS‐HA)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 0.9 normal saline (NS)
Number of subjects: 39
Study: 23548062

Group type: EXPERIMENTAL
Intervention: 4% dimeticone liquid gel applied once for 15 minutes
Number of subjects: 90

Group type: COMPARATOR
Intervention: 1% permethrin creme rinse applied for 10 minutes, repeated after 7 days
Number of subjects: 90
Study: 21423028

Group type: EXPERIMENTAL
Intervention: Irbesartan (300 mg/d)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 18182188

Group type: COMPARATOR
Intervention: Laboratory and clinical remount procedures with occlusal corrections (Group LCRO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Only laboratory remount with occlusal corrections (Group LRO)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Routine procedures without remount corrections (Group OOC)
Number of subjects: 30
Study: 16541858

Group type: EXPERIMENTAL
Intervention: Acupuncture once daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Acupuncture twice each week
Number of subjects: 49
Study: 14719212

Group type: EXPERIMENTAL
Intervention: Etidronate (200 mg per day for 2 weeks) with 3.0 g calcium lactate and 0.75 microg alphacalcidol
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control (3.0 g calcium lactate and 0.75 microg alphacalcidol)
Number of subjects: 102
Study: 11272799

Group type: EXPERIMENTAL
Intervention: Electroacupuncture and conventional therapy for four weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 20
Study: 8857480

Group type: EXPERIMENTAL
Intervention: Extended-length participation in cardiac rehabilitation (CRP) for >1 year
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard-length participation in cardiac rehabilitation (CRP) for 3 months
Number of subjects: 50
Study: 1474179

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Clonazepam
Number of subjects: 28

Group type: COMPARATOR
Intervention: Diphenhydramine (Control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 28
Study: 6880227

Group type: EXPERIMENTAL
Intervention: Cimetidine 1 g/day for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine 400 mg at night after full-dose course
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cimetidine (both dosages)
Number of subjects: 0
Study: 29334322

Group type: EXPERIMENTAL
Intervention: Antidepressant treatment
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: BDNF exon IV and p11 promoter methylation
Number of subjects: 110
Study: 30107787

Group type: EXPERIMENTAL
Intervention: Digitally supported personalised home‐based exercise training program (VITA group)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Digitally supported personalised home‐based exercise training program plus dietary protein counselling (VITA-Pro group)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Regular weekly exercise program (Control group)
Number of subjects: 240
Study: 27806243

Group type: COMPARATOR
Intervention: zidovudine alone
Number of subjects: 3490

Group type: EXPERIMENTAL
Intervention: zidovudine-based ART
Number of subjects: 3490

Group type: EXPERIMENTAL
Intervention: tenofovir-based ART
Number of subjects: 3490
Study: 24676931

Group type: EXPERIMENTAL
Intervention: Vorapaxar 2.5 mg daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study: 21778035

Group type: EXPERIMENTAL
Intervention: Meal Replacement (MR) with high soy protein content and low glycemic index (GI)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Standardized breakfast with high GI and low protein content
Number of subjects: 11
Study: 20034615

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 17327539

Group type: EXPERIMENTAL
Intervention: Four-session group intervention based on proactive coping theory
Number of subjects: 158

Group type: COMPARATOR
Intervention: Waiting control group
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Four-session group intervention
Number of subjects: 158
Study: 15766835

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 5030

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 5030
Study: 12202968

Group type: EXPERIMENTAL
Intervention: Selegiline (10 mg/day)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 10440457

Group type: EXPERIMENTAL
Intervention: Haloperidol with Carbamazepine (CBZ)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Haloperidol with Valproate (VPA)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 27
Study: 7783110

Group type: EXPERIMENTAL
Intervention: Felodipine ER (mean daily dose 11.2 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Amlodipine (mean daily dose 7.4 mg)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Felodipine ER
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 118
Study: 1970266

Group type: EXPERIMENTAL
Intervention: ICI 141,292 (Visacor) 50 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ICI 141,292 (Visacor) 100 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ICI 141,292 (Visacor) 200 mg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: ICI 141,292 (Visacor) 300 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6253100

Group type: EXPERIMENTAL
Intervention: Cyclizine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cyclizine and Metoclopramide (combination)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Nabilone and Metoclopramide (unrandomized pilot study)
Number of subjects: 15
Study: 30898825

Group type: EXPERIMENTAL
Intervention: Supported self-management Smartphone app (My Journey 3) plus Treatment As Usual (TAU)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Treatment As Usual (TAU) only
Number of subjects: 40
Study: 28917577

Group type: EXPERIMENTAL
Intervention: Calcium Hydroxide (CH)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Biodentine
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Mineral Trioxide Aggregate (MTA)
Number of subjects: 169
Study: 25816197

Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of olmesartan and amlodipine
Number of subjects: 376
Study: 22930216

Group type: EXPERIMENTAL
Intervention: Partially absorbable polypropylene mesh (PA)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Conventional polypropylene mesh (PP)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 200
Study: 21849247

Group type: EXPERIMENTAL
Intervention: Conventional transarterial chemoembolization
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: DEB transarterial chemoembolization
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 67
Study: 19484832

Group type: EXPERIMENTAL
Intervention: Early iron supplementation (3-4 mg/kg/day orally from 2 weeks)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control (no iron until 60 days)
Number of subjects: 46
Study: 18755784

Group type: EXPERIMENTAL
Intervention: Health Risk Appraisal for Older Persons (HRA-O)
Number of subjects: 2503

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 2503
Study: 16252379

Group type: EXPERIMENTAL
Intervention: Early psychiatric intervention (mental health screening and referral to psychogeriatric service)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 106
Study: 11940751

Group type: EXPERIMENTAL
Intervention: Translaryngeal technique
Number of subjects: 100

Group type: COMPARATOR
Intervention: Forceps-dilational technique
Number of subjects: 100
Study: 10652638

Group type: EXPERIMENTAL
Intervention: Classical music
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Self-selected relaxing music
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: No music
Number of subjects: 56

Group type: COMPARATOR
Intervention: Hard rock music
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: All conditions
Number of subjects: 56
Study: 7829787

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches (50 mg)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo patches
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches (50 mg) during patch-off period
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo patches during patch-off period
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Nitroglycerin patches (50 mg) during patch-on period
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo patches during patch-on period
Number of subjects: 52
Study: 2234817

Group type: EXPERIMENTAL
Intervention: Argon panretinal photocoagulation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Krypton panretinal photocoagulation
Number of subjects: 64
Study: 338397

Group type: EXPERIMENTAL
Intervention: Lotussin
Number of subjects: 50

Group type: COMPARATOR
Intervention: Linctus diphenhydramine
Number of subjects: 50
Study: 30958829

Group type: EXPERIMENTAL
Intervention: STRETCH (task shifting intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (ART)
Number of subjects: 0
Study: 27053062

Group type: EXPERIMENTAL
Intervention: Verum acupuncture
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Sham acupuncture
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waiting list
Number of subjects: 100
Study: 24934926

Group type: EXPERIMENTAL
Intervention: LOW group (2 sets of 20 repetition maximum)
Number of subjects: 58

Group type: COMPARATOR
Intervention: HIGH group (20 sets of 2 repetition maximum)
Number of subjects: 58

Group type: COMPARATOR
Intervention: STAND group (standardised rehabilitation protocol)
Number of subjects: 58
Study: 23295451

Group type: EXPERIMENTAL
Intervention: Video-assisted thoracoscopic lobectomy (VATS)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Open thoracotomy
Number of subjects: 66
Study: 21689025

Group type: EXPERIMENTAL
Intervention: Increased intake of salmon (two meals per week)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (habitual diet low in oily fish)
Number of subjects: 0
Study: 18234905

Group type: EXPERIMENTAL
Intervention: Short course antibiotic treatment (<= 5 days)
Number of subjects: 10698

Group type: COMPARATOR
Intervention: Conventional longer antibiotic treatment (> 5 days)
Number of subjects: 10698
Study: 16545881

Group type: EXPERIMENTAL
Intervention: PET/CT
Number of subjects: 21

Group type: COMPARATOR
Intervention: CT
Number of subjects: 21
Study: 14669316

Group type: EXPERIMENTAL
Intervention: N-acetyl cysteine (NAC) 200 mg orally three times daily (600 mg/day)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 41
Study: 11027739

Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 1041
Study: 8996853

Group type: EXPERIMENTAL
Intervention: New sustained-release theophylline formulation (T1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New sustained-release theophylline formulation (T2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pellet formulation (R)
Number of subjects: 0
Study: 1613812

Group type: EXPERIMENTAL
Intervention: Nimodipine, 2 mg/h iv for 2 days
Number of subjects: 351

Group type: COMPARATOR
Intervention: Control
Number of subjects: 351
Study: 6238545

Group type: EXPERIMENTAL
Intervention: Ipratropium (active drug)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 13
Study: 31257979

Group type: EXPERIMENTAL
Intervention: Body Awareness Rating Scale - Movement Quality and Experience
Number of subjects: 35
Study: 30846347

Group type: EXPERIMENTAL
Intervention: Simulation training on a triangulation simulation model (30 minutes of training for 4 consecutive days)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No training
Number of subjects: 36
Study: 29627227

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 69